These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3717976)

  • 41. Ultrasound as a screening procedure for methotrexate-induced hepatic damage in severe psoriasis.
    Miller JA; Dodd H; Rustin MH; Lees WR; Levene GM; Kirby JD; Munro DD
    Br J Dermatol; 1985 Dec; 113(6):699-705. PubMed ID: 3913457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatotoxicity of methotrexate in the treatment of psoriasis.
    Roenigk HH; Bergfeld WF; St Jacques R; Owens FJ; Hawk WA
    Arch Dermatol; 1971 Mar; 103(3):250-61. PubMed ID: 5548272
    [No Abstract]   [Full Text] [Related]  

  • 43. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment.
    Rosenberg P; Urwitz H; Johannesson A; Ros AM; Lindholm J; Kinnman N; Hultcrantz R
    J Hepatol; 2007 Jun; 46(6):1111-8. PubMed ID: 17399848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical pharmacokinetics of methotrexate in psoriasis therapy.
    Hendel J
    Dan Med Bull; 1985 Dec; 32(6):329-37. PubMed ID: 3908004
    [No Abstract]   [Full Text] [Related]  

  • 45. Predictive value of HLA antigen for methotrexate-induced liver damage in patients with psoriasis.
    Pestana A; Halprin KM; Taylor JR; Schiff ER; Esquenazi V; Comerford M; Gomez C
    J Am Acad Dermatol; 1985 Jan; 12(1 Pt 1):26-9. PubMed ID: 3980800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methotrexate-associated liver disease in psoriatic patients.
    Griesman FA; Hammer CJ; Fenster LF
    Northwest Med; 1972 Aug; 71(8):609-12. PubMed ID: 5053597
    [No Abstract]   [Full Text] [Related]  

  • 47. Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption.
    Hendel J; Nyfors A
    Eur J Clin Pharmacol; 1984; 26(1):121-4. PubMed ID: 6714284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.
    Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ
    Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatic metabolic function in patients receiving long-term methotrexate therapy: comparison with topically treated psoriatics, patient controls and cirrhotics.
    Birnie GG; Fitzsimons CP; Czarnecki D; Cooke A; Scobie G; Brodie MJ
    Hepatogastroenterology; 1985 Aug; 32(4):163-7. PubMed ID: 2865199
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methrotrexate U.S.P. (amethopterin) and methotrexate sodium.
    Am J Hosp Pharm; 1973 Jun; 30(6):542-8. PubMed ID: 4709936
    [No Abstract]   [Full Text] [Related]  

  • 51. The relation of HL-A antigens to liver histology in methotrexate-treated psoriatics.
    Nyfors A; Svejgaard A
    Acta Derm Venereol; 1976; 56(3):235-8. PubMed ID: 59509
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic methotrexate therapy for psoriasis: past, present and future.
    Dogra S; Mahajan R
    Clin Exp Dermatol; 2013 Aug; 38(6):573-88. PubMed ID: 23837932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methotrexate in the treatment of psoriasis.
    Med Lett Drugs Ther; 1972 Jun; 14(12):41-2. PubMed ID: 4567562
    [No Abstract]   [Full Text] [Related]  

  • 54. Liver disease in psoriatics--An effect of methotrexate therapy?
    Shapiro HA; Trowbridge JO; Lee JC; Maibach HI
    Arch Dermatol; 1974 Oct; 110(4):547-51. PubMed ID: 4414499
    [No Abstract]   [Full Text] [Related]  

  • 55. [Methotrexate in the treatment of psoriasis].
    Grupper C; Bourgeois-Spinasse J
    Presse Med (1893); 1970 Sep; 78(37):1631-4. PubMed ID: 5455160
    [No Abstract]   [Full Text] [Related]  

  • 56. Cutaneous ulceration caused by methotrexate.
    Kazlow DW; Federgrun D; Kurtin S; Lebwohl MG
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl Case Reports):S197-8. PubMed ID: 12894123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methotrexate in psoriatic arthritis.
    Singh YN; Verma KK; Kumar A; Malaviya AN
    J Assoc Physicians India; 1994 Nov; 42(11):860-2. PubMed ID: 7868484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tempting liver fibrosis? Long-term psoriatic methotrexate therapy and heterozygous alpha1-antitrypsin deficiency.
    Mathew J; Igbokwe UO; Morley N; Burt AD
    Dermatology; 2006; 213(2):147-9. PubMed ID: 16902293
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical pharmacokinetics of methotrexate.
    Shen DD; Azarnoff DL
    Clin Pharmacokinet; 1978; 3(1):1-13. PubMed ID: 346283
    [No Abstract]   [Full Text] [Related]  

  • 60. Razoxane in the treatment of psoriasis.
    Hill GW; Roach M
    Br J Dermatol; 1980 Nov; 103(5):583-5. PubMed ID: 7437323
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.